| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (NCT01658319) | Case Comprehensive Cancer Center | 2011-05-01 |
| A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma (NCT01355783) | Eisai Inc. | 2011-03-01 |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01261247) | Mayo Clinic | 2011-01-17 |
| Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma (NCT01075321) | Mayo Clinic | 2011-01-10 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas (NCT01280526) | The Lymphoma Academic Research Organisation | 2011-01-01 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma (NCT01258998) | National Cancer Institute (NCI) | 2010-12-01 |
| Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (NCT01110135) | University of Washington | 2010-08-01 |
| A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma (NCT01169298) | Celgene | 2010-07-01 |
| Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma (NCT01129180) | Pierluigi Porcu | 2010-05-01 |
| Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (NCT01116154) | City of Hope Medical Center | 2010-05-01 |
| Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry (NCT01110733) | Acrotech Biopharma Inc. | 2010-02-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT00891072) | National Cancer Institute (NCI) | 2009-07-01 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (NCT00933985) | National Cancer Institute (NCI) | 2009-06-01 |
| Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma (NCT00888927) | Kyowa Kirin Co., Ltd. | 2009-05-01 |
| Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT00865969) | Spectrum Pharmaceuticals, Inc | 2008-12-15 |
| Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients (NCT01036399) | University of Bologna | 2008-11-01 |
| Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (NCT00632827) | University of California, San Francisco | 2008-07-01 |
| T-Cell Project: Epidemiologic Component (NCT00705809) | National Cancer Institute (NCI) | 2008-06-18 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma (NCT00426764) | Celgene | 2007-06-19 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma (NCT00458731) | National Cancer Institute (NCI) | 2007-05-01 |
| Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies (NCT00481871) | Acrotech Biopharma Inc. | 2007-05-01 |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies (NCT00406809) | AbbVie (prior sponsor, Abbott) | 2006-11-01 |
| The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL (NCT00441025) | Mahidol University | 2006-09-01 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (NCT00536601) | Roswell Park Cancer Institute | 2006-06-29 |
| Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma (NCT00136565) | Lymphoma Study Association | 2006-01-08 |
| A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas (NCT00274651) | Valerio Therapeutics | 2006-01-01 |
| A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma (NCT00337987) | Yale University | 2005-11-01 |
| Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma (NCT00131937) | National Cancer Institute (NCI) | 2005-10-01 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00118352) | Fred Hutchinson Cancer Center | 2005-03-01 |
| The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) (NCT00930605) | King Chulalongkorn Memorial Hospital | 2005-01-01 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT00101205) | National Cancer Institute (NCI) | 2004-11-01 |
| Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas (NCT01470066) | Chonnam National University Hospital | 2004-08-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies (NCT00072514) | Fred Hutchinson Cancer Center | 2003-08-01 |
| CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma (NCT01806337) | University of Göttingen | 2003-07-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT (NCT00791947) | University of Aarhus | 2001-10-01 |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma (NCT00007345) | National Cancer Institute (NCI) | 2001-03-08 |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant (NCT00571662) | University of Nebraska | 2000-12-08 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies (NCT01678443) | Fred Hutchinson Cancer Center | 1999-09-01 |
| Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma (NCT00003196) | Fred Hutchinson Cancer Center | 1997-09-01 |
| Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma (NCT00970385) | University Hospital, Grenoble | 1995-01-01 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |
| Karyopharm Expanded Access Program for Selinexor (NCT07215832) | Karyopharm Therapeutics Inc | |